Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, shares hot topics in renal cell carcinoma from the ASCO GU Cancers Symposium 2023, including updated data in cabozantinib and nivolumab showing a consistent overall-survival (OS) benefit, as well updated biomarker data for cabozantinib and nivolumab with PD-1 and PD-L1. Prof. Powles additionally highlights clinical trials to look out for in the future, including the Phase III CONTACT-03 (NCT04338269) trial investigating cabozantinib with atezlimzumab and a Phase III (NCT04195750) trial assessing belzutifan versus everolimus. This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть